Edition:
India

Interpace Diagnostics Group Inc (IDXG.OQ)

IDXG.OQ on NASDAQ Stock Exchange Capital Market

1.18USD
21 Nov 2017
Change (% chg)

-- (--)
Prev Close
$1.18
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
330,915
52-wk High
$19.80
52-wk Low
$0.72

Chart for

About

Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates... (more)

Overall

Beta: 1.70
Market Cap(Mil.): $35.91
Shares Outstanding(Mil.): 22.16
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 26.71 16.44
EPS (TTM): -- -- --
ROI: -- 9.19 10.62
ROE: -- 12.28 14.20

BRIEF-Interpace Diagnostics says Q3 sales up 27 pct

* Interpace diagnostics group reports third quarter 2017 financial results, business progress and recent accomplishments

13 Nov 2017

BRIEF-Interpace Diagnostics announces increased reimbursement for ThyGenX

* Interpace Diagnostics Group - ‍reimbursement for ThyGenx molecular test for indeterminate thyroid nodules will increase by 40% starting Jan 1, 2018​ Source text for Eikon: Further company coverage:

11 Oct 2017

BRIEF-Interpace Diagnostics ‍launches new lung cancer test MVPdX​

* Interpace Diagnostics Group Inc - ‍Launch of a new lung cancer test MVPdX​ Source text for Eikon: Further company coverage:

25 Sep 2017

BRIEF-Interpace Diagnostics Group Inc - ‍ assigned a new, discreet CPT code to facilitate reimbursement of Thyramir​

* Interpace Diagnostics Group Inc - ‍ assigned a new, discreet CPT code to facilitate reimbursement of Thyramir​

11 Sep 2017

BRIEF-Interpace Diagnostics announces renewal and extension of LabCorp national agreement

* Interpace Diagnostics announces renewal and extension of LabCorp national agreement

28 Aug 2017

BRIEF-Interpace Diagnostics reports Q2 ‍loss per share from cont ops of $0.65

* Interpace Diagnostics Group reports second quarter 2017 financial results, business progress and recent accomplishments

10 Aug 2017

BRIEF-Interpace Diagnostics launches product extension at world conference on thyroid cancer

* Interpace Diagnostics launches product extension at world conference on thyroid cancer Source text for Eikon: Further company coverage:

01 Aug 2017

BRIEF-Interpace Diagnostics says Cigna agreed to cover co's ThyGenx test for Cigna members

* Interpace diagnostics group inc - cigna agreed to cover interpace's thygenx test for cigna members nationwide, with coverage effective immediately Source text for Eikon: Further company coverage:

27 Jul 2017

BRIEF-Interpace Diagnostics announces national contract with Aetna

* Interpace Diagnostics announces national contract with Aetna

28 Jun 2017

BRIEF-Interpace Diagnostics announces coverage of thyroid test by Premera Blue Cross

* Interpace Diagnostics Group - Premera Blue cross agreed to cover co's Thyramir test for members located primarily in Washington, Oregon, and Alaska Source text for Eikon: Further company coverage:

26 Jun 2017

Earnings vs. Estimates